pentapeptide
Ipamorelin updates
Answer
2 changes for Ipamorelin in the last 12 months. Latest: 2026-07-16.
| Date | Type | What changed | Source |
|---|---|---|---|
| 2026-07-16 | Trial | New trial registered: Trifecta Research Study | Trial register ClinicalTrials.gov |
| 2026-04-16 | Action | Ohio Board of Pharmacy: board | Regulator Ohio Board of Pharmacy |
| 2024-09-18 | Federal Register | Federal Register notice: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated | Regulator Federal Register |
| 2023-12-04 | Action | California Board of Pharmacy: board | Regulator California Board of Pharmacy |
| 2022-04-27 | Recall | FDA recall, Class II: North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding. Lack of Assurance of Sterility: deviations from Current Good Manu | Regulator FDA enforcement reports |
| 2021-11-17 | Recall | FDA recall, Class II: Vita Pharmacy, LLC dba Talon Compounding Pharmacy. Lack of assurance of sterility | Regulator FDA enforcement reports |
| 2021-11-17 | Recall | FDA recall, Class II: Vita Pharmacy, LLC dba Talon Compounding Pharmacy. Lack of assurance of sterility | Regulator FDA enforcement reports |
| 2021-11-17 | Recall | FDA recall, Class II: Vita Pharmacy, LLC dba Talon Compounding Pharmacy. Lack of assurance of sterility | Regulator FDA enforcement reports |
| 2021-07-28 | Recall | FDA recall, Class II: Innoveix Pharmaceuticals Inc. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2020-12-23 | Recall | FDA recall, Class II: Advanced Nutriceuticals, LLC. Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products in | Regulator FDA enforcement reports |
| 2020-01-22 | Recall | FDA recall, Class II: Assurance Infusion. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-06-19 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Sterility Assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2019-02-20 | Recall | FDA recall, Class II: Promise Pharmacy, LLC. Lack of sterility assurance. | Regulator FDA enforcement reports |
| 2018-11-07 | Recall | FDA recall, Class II: Pharm D Solutions, LLC. Lack of Assurance of Sterility | Regulator FDA enforcement reports |
| 2018-09-05 | Recall | FDA recall, Class II: Pharmcore Inc.. Lack of assurance of sterility. | Regulator FDA enforcement reports |
| 2018-09-05 | Recall | FDA recall, Class II: Pharmcore Inc.. Lack of assurance of sterility. | Regulator FDA enforcement reports |
| 2011-01-20 | Trial | New trial registered: Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function | Trial register ClinicalTrials.gov |
| 2008-05-06 | Trial | New trial registered: Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus | Trial register ClinicalTrials.gov |
From ClinicalTrials.gov, EU CTIS, FDA labels, recalls, shortages and warning letters, the Federal Register, and regulators' published actions. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.